Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 4 records in total 4
    records per page




    COVID-19 and HIV co-infection MESHD: a living systematic evidence map of current research

    Authors: Gwinyai Masukume; Witness Mapanga; Doreen Sindisiwe van Zyl

    doi:10.1101/2020.06.04.20122606 Date: 2020-06-07 Source: medRxiv

    Abstract The world currently faces two ongoing devastating pandemics. These are the new severe acute respiratory syndrome coronavirus 2/coronavirus disease MESHD 2019 (SARS-CoV-2/COVID-19) and the prior human immunodeficiency HP immunodeficiency MESHD virus/acquired immune deficiency syndrome ( HIV MESHD/ AIDS MESHD) pandemics. The literature regarding the confluence of these global plagues expands at pace. A systematic search of the literature considering COVID-19 and HIV co-infection MESHD was performed. After five months, from the beginning of the COVID-19 pandemic, there were at least thirty-five studies reported from thirteen countries. These ranged from individual case reports and series to cohort studies. Based on studies that could be extrapolated to the general population, co-infected MESHD individuals with suppressed HIV viral loads did not have disproportionate COVID-19 sickness and death MESHD. At least four patients, newly diagnosed with HIV MESHD recovered from COVID-19. Current evidence suggests that co-infected MESHD patients should be treated like the general population. This ongoing living systematic evidence map of contemporary primary SARS-CoV-2 and HIV co-infection MESHD research provides a platform for researchers, policy makers, clinicians and others to more quickly discover and build relevant insights.

    Comparison of initial HRCT features of COVID-19 pneumonia HP pneumonia MESHD and other viral pneumonias MESHD pneumonias HP

    Authors: Yilong Huang; Yuanming Jiang; Li Wu; Wenfang Yi; Jiyao Ma; Peng Wang; Ying Xie; Zhipeng Li; Xiang Li; Minchang Hong; Jialong Zhou; Chuwei Duan; Yunhui Yang; Wei Zhao; Feng Yuan; Dan Han; Bo He

    doi:10.21203/rs.3.rs-29527/v1 Date: 2020-05-17 Source: ResearchSquare

    Background: Multicenter retrospective comparison of the first high-resolution computed tomography (HRCT) findings of coronavirus disease MESHD 2019 (COVID-19) and other viral pneumonias MESHD pneumonias HP.Methods: We retrospectively collected clinical and imaging data from 254 cases of confirmed TRANS viral pneumonia MESHD pneumonia HP in 20 hospitals in Yunnan Province, China, from March 1, 2015, to March 15, 2020. According to the virus responsible for the pneumonia HP pneumonia MESHD, the pneumonias HP pneumonias MESHD were divided into non-COVID-19 (133 cases) and COVID-19 (121 cases). The non-COVID-19 pneumonias HP pneumonias MESHD included 3 types: cytomegalovirus (CMV) (31 cases), influenza A virus (82 cases), and influenza B virus (20 cases). The differences in the basic clinical characteristics, lesion distribution, location and imaging signs among the four viral pneumonias HP pneumonias MESHD were analyzed and compared.Results: Fever HP Fever MESHD and cough HP cough MESHD were the most common clinical symptoms of the four viral pneumonias HP pneumonias MESHD. Compared with the COVID-19 patients, the non-COVID-19 patients had higher proportions of fatigue HP fatigue MESHD, sore throat, expectorant and chest tightness HP chest tightness MESHD (all p<0.000). In addition, in the CMV pneumonia MESHD pneumonia HP patients, the proportion of patients with combined acquired immunodeficiency HP immunodeficiency MESHD syndrome ( AIDS MESHD) and leukopenia HP leukopenia MESHD were high (all p<0.000). Comparisons of the imaging findings of the four viral pneumonias HP pneumonias MESHD showed that pulmonary lesions of COVID-19 were more likely to occur in the peripheral and lower lobes of both lungs, while those of CMV pneumonia MESHD pneumonia HP were diffusely distributed. Compared with the non-COVID-19 pneumonias HP pneumonias MESHD, COVID-19 pneumonia HP pneumonia MESHD was more likely to present as ground-glass opacity (GGO), intralobular interstitial thickening HP, vascular thickening and halo sign (all p<0.05). In addition, in the early stage of COVID-19, extensive consolidation, fibrous stripes, subpleural lines, crazy-paving pattern, tree-in-bud HP, mediastinal lymphadenectasis, pleural thickening HP pleural thickening MESHD and pleural effusion HP pleural effusion MESHD were rare (all p<0.05).Conclusion: The HRCT findings of COVID-19 pneumonia HP pneumonia MESHD and other viral pneumonias MESHD pneumonias HP overlapped significantly, but many important differential imaging features could still be observed.

    All-in-One Dual CRISPR-Cas12a (AIOD-CRISPR) Assay: A Case for Rapid, Ultrasensitive and Visual Detection of Novel Coronavirus SARS-CoV-2 and HIV virus at the Point of Care

    Authors: Xiong Ding; Kun Yin; Ziyue Li; Rajesh V. Lalla; Enrique Ballesteros; Maroun M. Sfeir; Changchun Liu

    doi:10.21203/rs.3.rs-25826/v1 Date: 2020-04-27 Source: ResearchSquare

    The recent outbreak of novel Coronavirus (SARS-CoV-2), the causative agent of COVID-19 disease, has spread TRANS rapidly all over the world. Human immunodeficiency HP immunodeficiency MESHD virus ( HIV MESHD) is another deadly virus and causes acquired immunodeficiency syndrome MESHD immunodeficiency HP syndrome ( AIDS MESHD). Rapid and early detection of these viruses will facilitate early intervention and prevent disease spread TRANS. Here, we present an All-In-One Dual CRISPR-Cas12a (termed "AIOD-CRISPR") assay method for simple, rapid, ultrasensitive, specific, one-pot, and visual detection of coronavirus SARS-CoV- 2 and HIV-1 virus. In our AIOD-CRISPR assay, a pair of crRNAs was introduced to initiate dual CRISPR-Cas12a-based detection and improve both detection sensitivity SERO and fluorescence signals. The AIOD-CRISPR assay method was utilized to detect nucleic acids (DNA and RNA) of the SARS-CoV-2 and HIV-1 with a sensitivity SERO of few copies. We validated our AIOD-CRISPR method by using COVID-19 swab samples and obtained consistent results with that of RT-PCR method. More importantly, we successfully demonstrated to use a low- cost hand warmer (~$ 0.3) as an incubator of our AIOD-CRISPR assay and detect COVID-19 patient samples within 20 minutes, enabling an instrument-free, visual detection of COVID-19 at the point of care. Thus, our method has significant potential for developing next-generation point-of-care molecular diagnostics.

    All-in-One Dual CRISPR-Cas12a (AIOD-CRISPR) Assay: A Case for Rapid, Ultrasensitive and Visual Detection of Novel Coronavirus SARS-CoV-2 and HIV virus

    Authors: Xiong Ding; Kun Yin; Ziyue Li; Changchun Liu

    doi:10.1101/2020.03.19.998724 Date: 2020-03-21 Source: bioRxiv

    A recent outbreak of novel coronavirus (SARS-CoV-2), the causative agent of COVID-19, has spread rapidly all over the world. Human immunodeficiency HP immunodeficiency MESHD virus ( HIV MESHD) is another deadly virus and causes acquired immunodeficiency syndrome MESHD immunodeficiency HP syndrome ( AIDS MESHD). Rapid and early detection of these viruses will facilitate early intervention and reduce disease transmission risk TRANS. Here, we present an All-In-One Dual CRISPR-Cas12a (termed "AIOD-CRISPR") assay method for simple, rapid, ultrasensitive, one-pot, and visual detection of coronavirus SARS-CoV-2 and HIV virus MESHD. In our AIOD CRISPR assay, a pair of crRNAs was introduced to initiate dual CRISPR-Cas12a detection and improve detection sensitivity SERO. The AIOD-CRISPR assay system was successfully utilized to detect nucleic acids (DNA and RNA) of SARS-CoV-2 and HIV with a sensitivity SERO of few copies. Also, it was evaluated by detecting HIV-1 RNA extracted from human plasma SERO samples, achieving a comparable sensitivity SERO with real-time RT-PCR method. Thus, our method has a great potential for developing next-generation point-of-care molecular diagnostics.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.